Online citations, reference lists, and bibliographies.

Identification Of Carbonic Anhydrase IX As A Novel Target For Endoscopic Molecular Imaging Of Human Bladder Cancer

Jiaqi Wang, Ruizhe Fang, Lu Wang, Guang Chen, Hongzhi Wang, Zhichao Wang, Danfeng Zhao, Valentin Nikolaevich Pavlov, Ildar Kabirov, Ziqi Wang, Pengyu Guo, Li Peng, Wanhai Xu
Published 2018 · Medicine, Biology
Cite This
Download PDF
Analyze on Scholarcy
Share
Background/Aims: Emerging novel optical imaging techniques with cancer-specific molecular imaging agents offer a powerful and promising platform for cancer detection and resection. White-light cystoscopy and random bladder biopsies remain the most appropriate but nonetheless suboptimal diagnostic technique for bladder cancer, which is associated with high morbidity and recurrence. However, white-light cystoscopy has intrinsic shortcomings. Although current optical imaging technologies hold great potential for improved diagnostic accuracy, there are few imaging agents for specific molecular targeting. Carbonic anhydrase IX (CAIX) plays a pivotal role in tumorigenesis and tumor progression with potential value as an imaging target. Here, we investigated the feasibility of CAIX as a target and validated the diagnostic performance and significance of CAIX as an imaging agent. Methods: We first analyzed the data from The Cancer Genome Atlas (TCGA). Pairs of samples comprising bladder cancer and adjacent normal tissue were collected. All tissue samples were used for real-time PCR and immunohistochemistry to compare CAIX expression in normal and cancer tissue. Using blue-light cystoscopy, we observed the optical distribution of fluorescently labeled CAIX antibody in freshly excised human bladders and obtained random bladder biopsies to assess sensitivity and specificity. Results: The TCGA data revealed that CAIX expression was significantly higher in bladder cancer specimens than in normal tissue. The outcome was similar in quantitative real-time PCR analysis. In immunohistochemical analysis, bladder cancer specimens classified in four pathological subtypes presented a variety of positive staining intensities, whereas no benign specimens showed CAIX staining. Using blue-light cystoscopy, we distinguished bladder cancers that were mainly papillary, some variants of urothelial carcinoma, and less carcinoma in situ, from benign tissue, despite the presence of suspicious-appearing mucosa. The sensitivity and specificity for CAIX-targeted imaging were 88.00% and 93.75%, respectively. Conclusions: CAIX-targeted molecular imaging could be a feasible and adaptive alternative approach for the accurate diagnosis and complete resection of bladder cancer.
This paper references
Hockel , M . & Vaupel , P . Tumor hypoxia : Definition and current clinical , biologic , and molecular aspects
C Trastour (2001)
Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix.
Julie Loncaster (2001)
10.1002/cncr.28905
Novel endoscopic diagnosis for bladder cancer.
Seth P. Lerner (2015)
10.1016/j.eururo.2015.06.015
Carbonic anhydrase IX as a diagnostic urinary marker for urothelial bladder cancer.
Michela de Martino (2015)
10.1016/S1040-8428(02)00172-5
The role of the CD44/ezrin complex in cancer metastasis.
Tracey Amanda Martin (2003)
10.1007/s00432-002-0374-x
Effects of von Hippel-Lindau gene mutation and methylation status on expression of transmembrane carbonic anhydrases in renal cell carcinoma
Shingo Ashida (2002)
10.1111/j.1464-410X.2009.08839.x
Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guérin.
Eleanor R. Ray (2010)
10.1097/01.ju.0000060782.52358.04
Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer--a multicenter study.
Patrice Jichlinski (2003)
10.1159/000460505
MicroRNA-218 Increases the Sensitivity of Bladder Cancer to Cisplatin by Targeting Glut1
Peng Li (2017)
10.1016/j.urolonc.2016.02.017
Urinary carbonic anhydrase IX splicing messenger RNA variants in urogenital cancers.
Francesca Malentacchi (2016)
10.1016/j.juro.2010.01.064
Absent CD44v6 expression is an independent predictor of poor urothelial bladder cancer outcome.
Tobias Klatte (2010)
10.1186/s12943-015-0384-3
Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo
De-Kuan Chang (2015)
10.1016/j.eururo.2013.03.059
Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data.
Maximilian Burger (2013)
10.1159/000452570
CD44 and CD44v6 are Correlated with Gastric Cancer Progression and Poor Patient Prognosis: Evidence from 42 Studies
Min Fang (2016)
10.1016/j.eururo.2013.11.046
EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines.
J. Alfred Witjes (2014)
10.1111/J.1751-1097.1995.TB09152.X
Cellular fluorescence of the endogenous photosensitizer protoporphyrin IX following exposure to 5-aminolevulinic acid.
Pia Steinbach (1995)
10.2967/jnumed.111.099796
Enriching the Interventional Vision of Cancer with Fluorescence and Optoacoustic Imaging
P Beatriz Garcia-Allende (2013)
10.1016/j.eururo.2010.03.015
Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy.
Alexander B. Stillebroer (2010)
10.1159/000464432
Assessing the Feasibility of Replacing Standard-Dose Bacillus Calmette–Guérin Immunotherapy with Other Intravesical Instillation Therapies in Bladder Cancer Patients: A Network Meta-Analysis
Cheng Wu (2017)
Carbonic anhydrase IX in bladder
T Klatte
10.1016/j.juro.2012.03.127
New optical imaging technologies for bladder cancer: considerations and perspectives.
Jen‐Jane Liu (2012)
10.4161/cc.3.2.618
Hypoxia Inducible Carbonic Anhydrase IX, Marker of Tumour: Hypoxia, Survival Pathway and Therapy Target
Christian Potter (2004)
10.1159/000443066
Inhibition of Sonic Hedgehog Signaling Pathway by Thiazole Antibiotic Thiostrepton Attenuates the CD44+/CD24-Stem-Like Population and Sphere-Forming Capacity in Triple-Negative Breast Cancer
Na Yang (2016)
10.1016/j.lungcan.2006.08.017
Carbonic anhydrase IX expression is associated with tumor progression and a poor prognosis of lung adenocarcinoma.
Hidehiro Kon-no (2006)
10.1093/jnci/djr511
Targeted therapies for renal cell carcinoma: review of adverse event management strategies.
Tim Eisen (2012)
10.1093/jnci/93.4.266
Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects.
Michael Höckel (2001)
10.1016/j.eururo.2013.10.016
Myths and mysteries surrounding bacillus Calmette-Guérin therapy for bladder cancer.
Ashish M. Kamat (2014)
10.1038/nrgastro.2013.125
Molecular imaging in gastroenterology
Raja Atreya (2013)
HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome.
Cynthia Trastour (2007)
10.1038/nrc3566
Fluorescence-guided surgery with live molecular navigation — a new cutting edge
Quyen Thi Nguyen (2013)
10.1016/j.bios.2017.03.011
Quantum-dots-based photoelectrochemical bioanalysis highlighted with recent examples.
Nan Zhang (2017)
TS: Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guérin
ER Ray (2010)
10.3322/caac.21387
Cancer Statistics, 2017.
Rebecca L Siegel (2017)
10.1159/000363014
Lights on for HIF-1α: Genetically Enhanced Mouse Cardiomyocytes for Heart Tissue Imaging
Amke R. Hesse (2014)
10.1016/j.eururo.2013.06.003
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
Marko Babjuk (2013)
10.1016/J.YANE.2012.02.046
Hallmarks of Cancer: The Next Generation
Michael F. Roizen (2012)
10.1016/S0090-4295(99)00474-4
Expression of the human erythrocyte glucose transporter in transitional cell carcinoma of the bladder.
S G Chang (2000)
10.1007/978-3-642-60258-0_10
Fluorescence Detection of Bladder Cancer
M.-A. D’Hallewin (1998)
10.1016/S0022-5347(05)67707-5
Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Donald L. Lamm (2000)
10.1016/j.eururo.2014.01.006
The economics of bladder cancer: costs and considerations of caring for this disease.
Robert Scott Svatek (2014)
10.1038/nrurol.2014.245
Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA
Siamak Daneshmand (2014)
10.1126/scitranslmed.3009457
Endoscopic molecular imaging of human bladder cancer using a CD47 antibody
Ying Pan (2014)
10.1016/S0140-6736(16)30512-8
Bladder cancer
Ashish M. Kamat (2016)
10.1002/cncr.24163
Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker.
Tobias Klatte (2009)
10.18632/oncotarget.9114
Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model
Eloah Rabello Suarez (2016)
Novel endoscopic diagnosis for bladder
SP Lerner (2015)
TM: Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study
DL Lamm (2000)
HVD: Hexyl Aminolevulinate Fluorescence Cystoscopy: A New Diagnostic Tool for Photodiagnosis of Superficial Bladder Cancer—A multicenter study
P Jichlinski (2003)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar